trending Market Intelligence /marketintelligence/en/news-insights/trending/ZHA4RAozdNHm4sZrrFdLSA2 content esgSubNav
In This List

US district court rejects Teva patent infringement claims

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


US district court rejects Teva patent infringement claims

The U.S. District Court for the District of Delaware rejected Teva Pharmaceutical Industries Ltd.'s patent infringement claims against the generic versions of its multiple sclerosis drug Copaxone.

The court invalidated all asserted claims against five of the six drug applications for a generic version of Copaxone. Mylan NV and Sandoz Inc. are two of the companies seeking to sell a generic version of Copaxone.

Teva plans to appeal the decision.